Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with T2D.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Donald Trump, at 78, is aggressively pursuing his second term, marked by significant policy changes and a noticeable physical ...

Weight loss injections boost the glucagon-like peptide-1 (GLP-1) hormone, which is a naturally produced hormone in the ...

The acronym GLP-1 has become an increasingly popular term in the health arena, especially in the context of weight loss.

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

A new study raises mental health concerns about popular weight loss drugs like Ozempic and Mounjaro. These GLP-1 agonists, while effective for appetite control, may disrupt dopamine pathways linked to ...